Highest-materiality recent filing
Nautilus Biotechnology Q1 loss narrows to $14.7M; cash $143.4M
Net loss of $14.7M vs $16.6M in Q1 2025; operating expenses down 14% YoY to $16.1M.
Nautilus Biotechnology FY2025 net loss narrows to $59M; cash $156M; guidance for higher 2026 spend
Q4 net loss of $13.8M vs $17.6M YoY; operating expenses down 23% to $15.4M.
Nautilus regains Nasdaq minimum bid price compliance; deficiency closed
Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.
Nautilus Biotechnology Q3 2025 net loss $13.6M; operating expenses down 19% to $15.5M
Net loss of $13.6M for Q3 2025, improved from $16.4M loss in Q3 2024.
Nautilus Q2 net loss narrows to $15.0M; cash $179.5M; platform milestone
Operating expenses $17.1M, down 18% YoY from $20.8M.
Nautilus Biotechnology elects Class I directors, ratifies PwC, reduces board size to 7
Sujal Patel re-elected with 84.3M votes for; Matthew McIlwain elected with 82.2M votes for.
Received notice on May 1, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days through April 30, 2025.
Nautilus Q1 net loss $16.6M, operating expenses down 13% YoY
Net loss $16.6M, improved from $18.7M in Q1 2024.
Q4 2024 operating expenses flat at $20.0M; FY2024 op. expenses $81.5M (+7% YoY).
Two Nautilus Biotechnology directors not standing for re-election at 2025 annual meeting
Vijay Pande informed company on Jan 27, 2025, that he will not stand for re-election.
Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M
Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.
Nautilus Biotechnology reports Q2 2024 net loss of $18M, operating expenses up 9% YoY
Net loss of $18.0M in Q2 2024 vs $15.8M in Q2 2023.
Nautilus Biotechnology announces 2024 annual meeting voting results
Elected Melissa Epperly (92.1M for, 674K withheld), Matthew L. Posard (90.6M for, 2.1M withheld), Karen Akinsanya (89.9M for, 2.8M withheld) as Class III directors.
Nautilus Q1 net loss $18.7M vs $15.0M YoY; cash $247.7M
Net loss of $18.7M widened from $15.0M in Q1 2023; no revenue reported.
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
Matthew McIlwain agreed to resign as a Class II director, effective as of the opening of the polls for the election of Class I directors at the Annual Meeting, and to stand for election to the Board as a Class I director at the Annual Meeting
each of Vijay Pande and Michael Altman, respectively, informed the Company that he will not stand for re-election to the Company’s board of directors
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
On January 27 and 28, 2025, each of Vijay Pande and Michael Altman, respectively, informed Nautilus Biotechnology, Inc. (the “Company”) that they will not stand for re-election to the Company’s board of directors at the Company’s 2025 annual meeting of stockholders.
Max materiality 0.75 · Median 0.50 · Most common event earnings